Thomson Reuters Life Sciences Cortellis Competitive Intelligence Reaches Content Milestones
PHILADELPHIA, July 24, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced a series of industry-first milestones in its Cortellis platform. Cortellis, the premier source of life sciences competitive intelligence information and analytics, has reached new content milestones with more than 50,000 investigational drugs, 400,000 bioactive compounds, and six million biologically active patents. In total, the solution contains over 15 million expert, human-curated reports featuring deal information, patents, literature and clinical trials data.
The Cortellis milestones are in addition to new data being integrated into the platform as a result of three recent acquisitions. These include Deloitte Recap, the leading biopharmaceutical provider of life science deals, acquisitions data and analytics; BioWorld and Medical Device Daily, premiere daily news sources in the biopharma and medical device industries; and Timely Data Resources, the esteemed provider of epidemiology information for biopharmaceutical companies, device manufacturers, universities and research institutions. This collective content confirms Cortellis as the industry leading solution for drug discovery, development and commercialization.
"Given the overwhelming amount of public data available, life science professionals need a way to access accurate and relevant information and analytics to support strategic decisions throughout the drug development process," said Jon Brett-Harris, managing director, Thomson Reuters Life Sciences. "Their need underscores the reasoning behind our editorial process and unique Cortellis technology: make the best content findable and actionable for our pharmaceutical customers. Our recent milestones in content breadth, as well as our recent acquisitions, add to the decision-making power we give these professionals."
Thomson Reuters employs a rigorous review process for each investigational drug featured in Cortellis. The editorial team combs through two-to-three year's worth of information, compiling a unique profile that includes basic drug information as well as recent news articles, publications, events, and more. Users benefit from an all-in-one-place summary of the compound, without having to spend days researching and parsing information on their own.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts